BMPR1A

Bone morphogenetic proteins (BMPs), members of the transforming growth factor-beta (TGF-β) superfamily, play critical roles in embryogenesis, organogenesis, and tissue homeostasis. BMPs mediate their effects through BMP receptors, which include both type I and type II serine/threonine kinase receptors. Among these, bone morphogenetic protein receptor type IA (BMPR1A) has received considerable attention as a critical mediator of BMP signaling. Dysregulation of BMPR1A has been implicated in a variety of diseases, including cancer, fibrosis, cardiovascular disease, and hereditary syndromes such as juvenile polyposis syndrome. These pathological associations position BMPR1A as a promising drug target with therapeutic potential in oncology, regenerative medicine and fibrosis management.

NCBI Gene ID: 657

UniProtKB ID: P36894

Structure and Function of BMPR1A

BMPR1A, also known as ALK3 (activin receptor-like kinase 3), is a type I receptor that forms a heteromeric complex with BMP type II receptors upon ligand binding. The receptor consists of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular serine/threonine kinase domain.

Upon BMP binding, BMPR1A is phosphorylated by type II receptors, activating its kinase domain. This activation triggers downstream signaling cascades, primarily through the Smad-dependent pathway. In this canonical pathway, receptor-regulated Smads (Smad1, Smad5, and Smad8) are phosphorylated by BMPR1A and form a complex with Smad4. This complex translocates to the nucleus to regulate target gene expression. Non-Smad pathways, such as those involving MAPK, PI3K/Akt and Rho GTPases, can also be activated, expanding the functional repertoire of BMPR1A signaling.

Figure 1. BMP signal transduction. (A) BMP signaling pathways. BMP ligands bind to type I and type II simultaneously which leads to activation of the Smad-dependent pathway. Activation, transport and regulation of target genes by R-Smads require Co-Smad. If BMP ligands bind to the type I receptors first and then recruit the type II receptors which activatesTAB1/2/3 through XIAP, this would lead to the activation of Smad independent MAPK pathway. Regulation of BMP signaling can occur extracellularly during the process of ligand binding to receptor, and intracellularly during the signal transduction. (B) BMPs and their specific receptors. Key downstream signaling molecules of BMP/GDF through the use of a dendrogram tree. (Ye and Jiang, 2016)

Pathological Implications of BMPR1A Dysregulation

BMPR1A is critical for maintaining cellular processes such as proliferation, differentiation and apoptosis. Aberrant signaling through BMPR1A has been associated with numerous pathological conditions, underscoring its therapeutic relevance.

• Cancer: BMPR1A plays a dual role in cancer, acting as either a tumor suppressor or promoter depending on the tissue context. Loss of BMPR1A function is associated with enhanced tumorigenicity in colorectal and gastric cancers, where it promotes epithelial cell proliferation and suppresses differentiation. Conversely, in glioblastoma and melanoma, BMPR1A signaling can drive tumor progression by inducing invasion and angiogenesis.
• Fibrosis: BMPR1A has been implicated in the regulation of fibrosis in multiple organs, including the liver, lung, and kidney. Dysregulated BMP signaling contributes to fibrotic diseases by modulating the activity of myofibroblasts, extracellular matrix production, and tissue remodeling.
• Hereditary Syndromes: Germline mutations in BMPR1A are a hallmark of juvenile polyposis syndrome (JPS), an autosomal dominant disorder characterized by gastrointestinal polyps and an increased risk of colorectal cancer.
• Cardiovascular Disorders: BMPR1A is essential for vascular homeostasis and heart development. Altered BMP signaling has been associated with pulmonary arterial hypertension (PAH) and congenital heart defects, suggesting therapeutic potential in the treatment of cardiovascular disease.

BMPR1A as A Drug Target

The pivotal role of BMPR1A in diverse cellular processes and diseases makes it an attractive drug target. Modulating BMPR1A activity—either through agonists or antagonists—has therapeutic implications across several disease contexts.

• Antibodies and Ligand Traps: Monoclonal antibodies and soluble ligand traps targeting BMP ligands or BMPR1A have been developed to modulate receptor activity. For example, Noggin, a natural antagonist of BMPs, can inhibit excessive BMP signaling by sequestering ligands, thereby reducing fibrosis and inflammation.
• Gene Therapy: Gene editing approaches targeting BMPR1A or its downstream signaling components hold potential for the treatment of inherited disorders such as JPS. CRISPR-Cas9-based strategies could be used to correct BMPR1A mutations, thereby restoring normal signaling and preventing disease progression.
• Regenerative Medicine: BMPR1A agonists are being investigated in the context of bone regeneration and repair. Enhancing BMP signaling through BMPR1A activation promotes osteogenesis and chondrogenesis, offering therapeutic opportunities for osteoporosis, non-union fractures and cartilage repair.

Dibotermin Alfa Target BMPR1A

Dibotermin alfa (recombinant human bone morphogenetic protein-2, rhBMP-2) is a biologic therapy designed to promote bone healing and regeneration. It is a recombinant version of a naturally occurring protein, bone morphogenetic protein-2 (BMP2), which plays a critical role in the formation of bone and cartilage. Dibotermin alfa specifically targets the bone morphogenetic protein receptor, type IA (BMPR-IA), a receptor found on the surface of cells involved in bone formation.

By binding to BMPR-IA, dibotermin alfa activates a signaling pathway that stimulates the differentiation of mesenchymal stem cells into osteoblasts (bone-forming cells), thereby promoting bone growth and repair. This makes it particularly useful in treating conditions where bone healing is compromised, such as spinal fusion surgery or fractures that are difficult to heal naturally.

Key Features and Applications

• Bone Regeneration: Dibotermin alfa accelerates the formation of new bone tissue, supporting healing in patients undergoing spinal fusion or other orthopedic procedures.
• Clinical Use: It is commonly used in patients with non-union fractures, degenerative disc disease, or spinal fusion procedures to improve bone healing and reduce the need for autograft (bone taken from the patient).
• Mechanism of Action: By targeting BMPR-IA, dibotermin alfa activates the BMP signaling pathway, promoting osteogenesis (bone formation) and improving the overall healing process.

Benefits

• Enhanced Bone Healing: It supports faster and more effective bone repair in cases of delayed or non-union fractures.
• Reduced Surgical Risks: Dibotermin alfa helps minimize the need for harvesting bone from the patient, reducing the risk of donor site complications.

Side Effects and Considerations

• Potential Side Effects: Some patients may experience local swelling, pain at the injection site, or inflammatory reactions. There is also a risk of abnormal bone formation in certain conditions.
• Contraindications: Dibotermin alfa is not recommended in patients with conditions that may cause abnormal bone growth or in patients with active infection at the surgical site.

Creative BioMart is a trusted provider of therapeutic proteins, including dibotermin alfa. Contact us with any questions or inquiries.

References

1. Lim J, Shi Y, Karner CM, et al. Dual function of BMPR1A signaling in restricting preosteoblast proliferation and stimulating osteoblast activity in the mouse. Development. Published online January 1, 2015:dev.126227.
2. Ye L, Jiang WG. Bone morphogenetic proteins in tumour associated angiogenesis and implication in cancer therapies. Cancer Letters. 2016;380(2):586-597.